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Psoriasis, a chronic cutaneous inflammatory dis-
ease, is an immune-mediated disorder caused by
complex interactions between dendritic cells, T cells,
and keratinocytes. Tumor necrosis factor alfa (TNF-
a) is a cytokine that plays a major role in the
inflammatory cascade.1 Biologic agents that target
TNF-a such as etanercept, infliximab, and adalimu-
mab are effective in the treatment of psoriasis.2
Psoriasis has been described as a systemic inflam-
matory disease, given its association with comorbid
conditions such as cardiovascular disease, metabolic
syndrome, and psoriatic arthritis.1 Of note, other
autoimmune diseases such as inflammatory bowel
disease (IBD), primary sclerosing cholangitis, celiac
disease, systemic sclerosis, and alopecia areata are
reported to occur with a higher prevalence in
patients with psoriasis.3-5 The relationship between
psoriasis and IBD may be related to the overlapping
role of T-helpere17 cells, interleukin-12, interleukin-
23, and TNF-a in the pathogenesis of these inflam-
matory disorders.3
There is a dearth of literature regarding the
treatment of psoriasis with biologic agents in patients
with organ transplants. Given the immunosuppres-
sive regimens of the posttransplant population, pso-
riasis flares are uncommon and are thus a challenge
to treat.6 Treating psoriasis with additional immuno-
suppression poses significant risks, including the
increased risk of infection. This article describes the
efficacy of using etanercept in a patient with psori-
asis and ulcerative colitis/primary sclerosing chol-
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g.CASE REPORT
A 52-year-old white woman with a 10-year history
of plaque psoriasis presented with a moderate-to-
severe flare of plaque psoriasis in the setting of
immunosuppressive therapy for a liver transplant
performed 5 years prior. The patient had a history of
primary sclerosing cholangitis, ulcerative colitis after
colectomy and J-pouch, and gallbladder carcinoma
in remission. Her psoriasis began to flare after her
transplant, and she was subsequently treated with
topical triamcinolone acetonide, clobetasol propio-
nate, and calcipotriol as well as narrow-band ultra-
violet B phototherapy, but these treatments were not
helpful. The posttransplantation immunosuppres-
sive regimen included tacrolimus, 3 mg daily, pred-
nisone, 5 mg daily, and everolimus, 0.25 mg daily.
Previous use of mycophenolate mofetil resulted in
worsening of psoriasis. Despite this immunosuppres-
sion, her flare involved 30% to 35% of her body
surface area. On physical examination, she had
erythematous nonscaly plaques on the bilateral
aspect of her legs and arms and guttate plaques,
some with scale, on her trunk. Her scalp was clear,
she hadpitting of her nails, and therewas no reported
joint involvement or features of psoriatic arthritis.
Topical treatment with triamcinolone acetonide
and calcipotriol was initiated, but the patientJAAD Case Reports 2015;1:S36-7.
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continued worsening of the psoriasis. Subsequent
discussion with the transplant team led to the deci-
sion to initiate treatment with the anti-TNF biological
agent, etanercept. Weekly injections of subcutane-
ous etanercept, 50 mg, were started with no modi-
fications to the patient’s posttransplantation
immunosuppressive regimen. Within a month of
initiating etanercept therapy, the patient’s lesions
improved dramatically. A month later, body surface
area involvement was less than 5% with only limited
involvement on her extremities. In addition, the
patient reported a decrease in the frequency of
episodes of pouchitis (inflammation of her J-pouch
created after her colectomy) after beginning
etanercept.
With regard to infection, the patient had a previ-
ous history of postprocedure cholangitis after an
endoscopic retrograde cholangiopancreatography
before to starting etanercept. One year after starting
etanercept therapy, the patient experienced multiple
infections including several episodes of asymptom-
atic urinary tract infections and multiple hospitaliza-
tions for recurrent cholangitis, requiring systemic
antibiotics. The etanercept was withheld during
hospital admissions and restarted at her standard
dosing after resolution of her infections. Her psori-
asis recurred when the etanercept was held but has
cleared each time it was restarted. At the time of the
writing of this report, the patient’s etanercept was
being held because of an infection.
DISCUSSION
This case shows the efficacy of etanercept in
treating psoriasis in an organ transplant patient.
The decision to initiate etanercept was made on the
basis that it targeted TNF-a, an arm of the immune
system not already targeted by our patient’s other
transplant medications. The patient was already
receiving tacrolimus, a calcineurin inhibitor, and
everolimus, a mechanistic target of rapamycin inhib-
itor. We considered cyclosporine as a potential
treatment, but because the patient was already taking
a calcineurin inhibitor, etanercept presented a better
choice in this case. If the patient is unable to continue
on etanercept in the future, altering her immuno-
suppression regimen from tacrolimus to cyclo-
sporine might be beneficial based on the
observation of Foroncewicz et al6 that cyclosporine
may have better efficacy for recurrent psoriasis than
tacrolimus.
The use of etanercept for psoriasis in posttrans-
plant patients has not been studied in clinical trials
but there are several reports of its efficacy in theliterature. To our knowledge, there have been 3
cases of patients with organ transplants, 2 liver and 1
pancreas-kidney, that have had marked improve-
ment of their severe psoriasis after treatment with
etanercept.7-10 There are also multiple reports of
patients with organ transplants who have had a
clinical response in their IBD after treatment with
other antieTNF-a agents, including infliximab and
adalimumab.9
Interestingly, our patient received an organ trans-
plant and had 2 diseases that typically respond to
TNF-a inhibitors, psoriasis, and ulcerative colitis.
The initiation of etanercept resolved her psoriasis,
and she reports a decrease in her pouchitis. The
patient’s infections are a reminder that blocking
multiple pathways of the immune system confers a
markedly higher risk of infection, and this must be
discussed carefully with patients and their transplant
team. The use of TNF-a inhibitors in organ transplant
patients should be used with caution, and further
study in a larger population is necessary to evaluate
the overall benefits and risks.
The authors acknowledge the clinical contribution of
Dr Hillel Tobias in the treatment of this patient.
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